For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.

What is the 340B Program? This program, administered by the Health Resources and Services Administration (HRSA), allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Hospitals use 340B savings to provide, for example, free care for uninsured patients, offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs. According to HRSA, enrolled hospitals and other covered entities can achieve average savings of 25% to 50% in pharmaceutical purchases.

Which organizations are eligible? Several types of hospitals are eligible to participate in the 340B program including critical access hospitals (CAHs), sole community hospitals (SCHs), rural referral centers (RRCs), public and private nonprofit disproportionate share hospitals (DSHs) that serve high numbers of low-income and indigent populations, and free-standing cancer and children’s hospitals. Several types of federal grantee organizations such as community health centers also are eligible to participate in the program.

What are some challenges to the program? Despite rigorous oversight from HRSA and the program’s proven record of expanding access to care for Americans nationwide, critics continue to push to diminish the scope of the program and the benefits it affords eligible providers and their patients.
 

340B Resources

Member Resources

Join the 340B Alliance Banner

The AHA Advocacy Alliance for the 340B program focuses on promoting the value that the 340B program provides to hospitals, patients and communities, as well as preventing attempts to scale back this program. Join the alliance for access to email communications, conference calls and special briefings. Join the Alliance.


Through email communications like alliance emails, action alerts and special messages, the 340B Alliance keeps hospitals informed of the latest news and developments on the program, as well as actions hospital leaders can take to support the program. Learn More

Image of medicine in pharmacy

Latest 340B Content

340B Advocacy Alliance Bulletin
AHA releases summaries of outpatient PPS and physician fee schedule rules that have 340B provisions.
Advisories
The CMS Nov. 4 issued a final rule that updates physician fee schedule payments for calendar year 2027.
Press Releases
CMS’ Medicare outpatient hospital payment rate does not adequately take into account the financial challenges facing hospitals today. These challenges are amplified for hospitals serving rural and underserved communities, many of which are already making hard decisions about how they will maintain access to healthcare services in their communities.
Headline
The AHA Oct. 27 submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act).
340B Advocacy Alliance Bulletin
The AHA yesterday submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act).
Letters/Comments
The SUSTAIN 340B Act represents a constructive bipartisan effort to establish clear and durable rules for all stakeholders in the program.
340B Advocacy Alliance Bulletin

Please encourage your House representatives to co-sponsor the 340B Rebate Model Delay Act (H.R. 10770), a bipartisan bill that would pause the Department of Health and Human Services 340B Rebate Model Pilot Program, currently set to go into effect Jan. 1, 2027.

Action Alerts
Please encourage your House representatives to co-sponsor the 340B Rebate Model Delay Act (H.R. 10770), a bipartisan bill that would pause the Department of Health and Human Services 340B Rebate Model Pilot Program, currently set to go into effect Jan. 1, 2027.
340B Advocacy Alliance Bulletin
AHA urges court to reject drug industry intervention in 340B rebate program case.
Headline
The U.S. District Court for the District of Maine should deny motions by several drug companies and Pharmaceutical Research and Manufacturers of America to intervene in the lawsuit challenging the administration’s revised 340B rebate model, the AHA and its co-plaintiffs argued in a filing submitted Oct. 21.